271 related articles for article (PubMed ID: 18794121)
1. Flt-1 signaling in macrophages promotes glioma growth in vivo.
Kerber M; Reiss Y; Wickersheim A; Jugold M; Kiessling F; Heil M; Tchaikovski V; Waltenberger J; Shibuya M; Plate KH; Machein MR
Cancer Res; 2008 Sep; 68(18):7342-51. PubMed ID: 18794121
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth.
Muramatsu M; Yamamoto S; Osawa T; Shibuya M
Cancer Res; 2010 Oct; 70(20):8211-21. PubMed ID: 20924106
[TBL] [Abstract][Full Text] [Related]
3. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes.
Aghi M; Cohen KS; Klein RJ; Scadden DT; Chiocca EA
Cancer Res; 2006 Sep; 66(18):9054-64. PubMed ID: 16982747
[TBL] [Abstract][Full Text] [Related]
4. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.
Valter MM; Hügel A; Huang HJ; Cavenee WK; Wiestler OD; Pietsch T; Wernert N
Cancer Res; 1999 Nov; 59(21):5608-14. PubMed ID: 10554042
[TBL] [Abstract][Full Text] [Related]
5. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
[TBL] [Abstract][Full Text] [Related]
6. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment.
Murakami M; Zheng Y; Hirashima M; Suda T; Morita Y; Ooehara J; Ema H; Fong GH; Shibuya M
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):658-64. PubMed ID: 18174461
[TBL] [Abstract][Full Text] [Related]
7. Soluble Flt-1 gene transfer ameliorates neointima formation after wire injury in flt-1 tyrosine kinase-deficient mice.
Koga J; Matoba T; Egashira K; Kubo M; Miyagawa M; Iwata E; Sueishi K; Shibuya M; Sunagawa K
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):458-64. PubMed ID: 19164801
[TBL] [Abstract][Full Text] [Related]
8. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
9. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
[TBL] [Abstract][Full Text] [Related]
10. VEGFR-1 signaling regulates the homing of bone marrow-derived cells in a mouse stroke model.
Beck H; Raab S; Copanaki E; Heil M; Scholz A; Shibuya M; Deller T; Machein M; Plate KH
J Neuropathol Exp Neurol; 2010 Feb; 69(2):168-75. PubMed ID: 20084017
[TBL] [Abstract][Full Text] [Related]
11. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.
Osterberg N; Ferrara N; Vacher J; Gaedicke S; Niedermann G; Weyerbrock A; Doostkam S; Schaefer HE; Plate KH; Machein MR
Neuro Oncol; 2016 Jul; 18(7):939-49. PubMed ID: 26951383
[TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth.
Ogawa Y; Suzuki T; Oikawa A; Hosono K; Kubo H; Amano H; Ito Y; Kitasato H; Hayashi I; Kato T; Sugimoto Y; Narumiya S; Watanabe M; Majima M
Biochem Biophys Res Commun; 2009 May; 382(4):720-5. PubMed ID: 19318087
[TBL] [Abstract][Full Text] [Related]
15. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization.
Li B; Sharpe EE; Maupin AB; Teleron AA; Pyle AL; Carmeliet P; Young PP
FASEB J; 2006 Jul; 20(9):1495-7. PubMed ID: 16754748
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
Deryugina EI; Soroceanu L; Strongin AY
Cancer Res; 2002 Jan; 62(2):580-8. PubMed ID: 11809713
[TBL] [Abstract][Full Text] [Related]
17. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.
Seetharam L; Gotoh N; Maru Y; Neufeld G; Yamaguchi S; Shibuya M
Oncogene; 1995 Jan; 10(1):135-47. PubMed ID: 7824266
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites.
Guo P; Xu L; Pan S; Brekken RA; Yang ST; Whitaker GB; Nagane M; Thorpe PE; Rosenbaum JS; Su Huang HJ; Cavenee WK; Cheng SY
Cancer Res; 2001 Dec; 61(23):8569-77. PubMed ID: 11731444
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.
Guleng B; Tateishi K; Ohta M; Kanai F; Jazag A; Ijichi H; Tanaka Y; Washida M; Morikane K; Fukushima Y; Yamori T; Tsuruo T; Kawabe T; Miyagishi M; Taira K; Sata M; Omata M
Cancer Res; 2005 Jul; 65(13):5864-71. PubMed ID: 15994964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
